Cargando…
Interleukin-6: a new therapeutic target
The therapeutic success of biological agents, especially the tumour necrosis factor (TNF) inhibitors, has opened a new chapter in the book of therapies for rheumatoid arthritis. Nevertheless, more than 50% of patients may not respond by > 50% improvement. New compounds have recently entered the t...
Autores principales: | Smolen, Josef S, Maini, Ravinder N |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3226077/ https://www.ncbi.nlm.nih.gov/pubmed/16899109 http://dx.doi.org/10.1186/ar1969 |
Ejemplares similares
-
Correction: Interleukin-6: a new therapeutic target
por: Smolen, Josef S, et al.
Publicado: (2006) -
Interleukin-6: a new therapeutic target in systemic sclerosis?
por: O'Reilly, Steven, et al.
Publicado: (2013) -
Current and new antitumor necrosis factor agents in perspective
por: Maini, Ravinder N
Publicado: (2004) -
Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor
por: Dayer, Jean-Michel, et al.
Publicado: (2010) -
B-cell targeted therapeutics in clinical development
por: Blüml, Stephan, et al.
Publicado: (2013)